m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT00469
 [1], [2], [3]
RNA modification MIR149 MIR149 ADAR Methylation : modification sites Indirect Enhancement m6A modification CXCL12 CXCL12 METTL3 Methylation : m6A sites
m6A Modification:
m6A Regulator Methyltransferase-like 3 (METTL3) WRITER
 Regulator Info 
m6A Target Stromal cell-derived factor 1 (CXCL12)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type RNA modification (RNAMod)  >> Adenosine-to-Inosine editing (A-to-I)
Epigenetic Regulator Interferon-inducible protein 4 (ADAR1) WRITER View Details
Regulated Target MicroRNA 149 (MIR149) View Details
Crosstalk Relationship A-to-I  →  m6A Enhancement
Crosstalk Mechanism RNA modification indirectly impacts m6A modification through downstream signaling pathways
Crosstalk Summary ADAR1 interacts with MicroRNA 149 (MIR149), increasing it's A-to-I level and promoting its physical interaction with Stromal cell-derived factor 1 (CXCL12), which was regulated by METTL3-mediated m6A modification.
In-vitro Model
 BRO Amelanotic melanoma Homo sapiens CVCL_7036
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Stromal cell-derived factor 1 (CXCL12) 5 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name MyoCell SDF-1 Phase 3 [4]
Synonyms
Autologous skeletal myoblast therapy (SDF-1, cardiovascular disease), Bioheart
    Click to Show/Hide
MOA Modulator
External Link
TTD: D0DR4W
 Compound Name Dociparstat sodium Phase 3 [5]
Synonyms
DSTAT
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D5VRX2
 Compound Name SDF-1 Phase 2 [6]
Synonyms
JVS-100
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D07YLO
 Compound Name NOX-A12 Phase 1 [7]
Synonyms
Ocular antineovascularisation agent/angiogenesis inhibitor (diabetic retinopathy/AMD), NOXXON; SDF-1 inhbitor (spiegelmer, stem cell transplantation), NOXXON; CXCL12 inhibitor (spiegelmer, diabetic retinopathy/AMD/stem cell transplantation), Noxxon
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0D8MG
 Compound Name REC-02 Phase 1 [8]
MOA Modulator
External Link
TTD: D0K6NW
References
Ref 1 Hypoxia Promotes Vascular Smooth Muscle Cell (VSMC) Differentiation of Adipose-Derived Stem Cell (ADSC) by Regulating Mettl3 and Paracrine Factors. Stem Cells Int. 2020 Feb 20;2020:2830565. doi: 10.1155/2020/2830565. eCollection 2020.
Ref 2 ADAR1p150 regulates the biosynthesis and function of miRNA-149* in human melanoma. Biochem Biophys Res Commun. 2020 Mar 19;523(4):900-907. doi: 10.1016/j.bbrc.2019.12.110. Epub 2020 Jan 17.
Ref 3 Hypermethylation of microRNA-149 activates SDF-1/CXCR4 to promote osteogenic differentiation of mesenchymal stem cells. J Cell Physiol. 2019 Dec;234(12):23485-23494. doi: 10.1002/jcp.28917. Epub 2019 Jun 17.
Ref 4 Stromal cell-derived factor-1 (SDF-1): homing factor for engineered regenerative medicine. Expert Opin Biol Ther. 2011 Feb;11(2):189-97.
Ref 5 Clinical pipeline report, company report or official report of Chimerix.
Ref 6 SDF-1 in myocardial repair. Gene Ther. 2012 Jun;19(6):583-7.
Ref 7 SDF-1/CXCR4/CXCR7 is pivotal for vascular smooth muscle cell proliferation and chronic allograft vasculopathy. Transpl Int. 2015 Dec;28(12):1426-35.
Ref 8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)